JP2009512663A5 - - Google Patents

Download PDF

Info

Publication number
JP2009512663A5
JP2009512663A5 JP2008536060A JP2008536060A JP2009512663A5 JP 2009512663 A5 JP2009512663 A5 JP 2009512663A5 JP 2008536060 A JP2008536060 A JP 2008536060A JP 2008536060 A JP2008536060 A JP 2008536060A JP 2009512663 A5 JP2009512663 A5 JP 2009512663A5
Authority
JP
Japan
Prior art keywords
powder
medicament
surfactant
pharmaceutical composition
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008536060A
Other languages
English (en)
Other versions
JP5873616B2 (ja
JP2009512663A (ja
Filing date
Publication date
Priority claimed from ITMI20051999 external-priority patent/ITMI20051999A1/it
Application filed filed Critical
Publication of JP2009512663A publication Critical patent/JP2009512663A/ja
Publication of JP2009512663A5 publication Critical patent/JP2009512663A5/ja
Application granted granted Critical
Publication of JP5873616B2 publication Critical patent/JP5873616B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. 医薬、可溶性賦形剤および界面活性剤を含む乾燥粉末形態の吸入用医薬組成物であって、
    − 上記の可溶性賦形剤が10重量%〜100重量%未満の量で存在し;
    − 上記の界面活性剤と上記の医薬との重量比が0.01〜10の間にあり;
    − 上記の粉末粒子の少なくとも50%の粒子径が5μmより小さく;
    − 上記の粉末の嵩密度dbが0.1〜0.3g/ccの間にあり;
    − 上記の粉末のタップ密度dtが0.15〜0.7g/ccの間にあり;
    − db/dtの比が0.2〜0.65の間にある
    ことを特徴とする吸入用医薬組成物。
JP2008536060A 2005-10-21 2006-10-20 乾燥粉末、またはそれから得られた溶液もしくは懸濁液の形態にある吸入用医薬組成物およびその製造方法 Active JP5873616B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2005A001999 2005-10-21
ITMI20051999 ITMI20051999A1 (it) 2005-10-21 2005-10-21 Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
PCT/EP2006/067619 WO2007045689A2 (en) 2005-10-21 2006-10-20 Inhalatory pharmaceutical compositions in form of dry powders, solutions or suspensions

Publications (3)

Publication Number Publication Date
JP2009512663A JP2009512663A (ja) 2009-03-26
JP2009512663A5 true JP2009512663A5 (ja) 2009-11-26
JP5873616B2 JP5873616B2 (ja) 2016-03-01

Family

ID=37806135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536060A Active JP5873616B2 (ja) 2005-10-21 2006-10-20 乾燥粉末、またはそれから得られた溶液もしくは懸濁液の形態にある吸入用医薬組成物およびその製造方法

Country Status (13)

Country Link
US (1) US9138407B2 (ja)
EP (1) EP1937229B1 (ja)
JP (1) JP5873616B2 (ja)
CY (1) CY1116503T1 (ja)
DK (1) DK1937229T3 (ja)
ES (1) ES2537777T3 (ja)
HU (1) HUE026045T2 (ja)
IT (1) ITMI20051999A1 (ja)
PL (1) PL1937229T3 (ja)
PT (1) PT1937229E (ja)
RU (1) RU2497507C2 (ja)
SI (1) SI1937229T1 (ja)
WO (1) WO2007045689A2 (ja)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
US7709639B2 (en) 2004-08-20 2010-05-04 Mannkind Corporation Catalysis of diketopiperazine synthesis
ES2543007T3 (es) 2004-08-23 2015-08-13 Mannkind Corporation Micropartículas que comprenden sales de dicetopiperazina para la administración de fármacos
WO2007033316A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1984049A1 (en) 2006-01-19 2008-10-29 Optinose AS Nasal administration
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8614236B2 (en) * 2006-12-12 2013-12-24 University Of Washington Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
SI3354276T1 (sl) 2007-11-13 2020-09-30 Meritage Pharma, Inc. Sestavki za zdravljenje gastrointestinalnega vnetja
DK2230934T3 (da) 2007-12-14 2012-11-26 Aerodesigns Inc Afgivelse af aerosoliserbare næringsmiddelprodukter
WO2009139506A1 (ja) * 2008-05-15 2009-11-19 Aspion株式会社 異なる物性の薬物の一剤形化
TWI611818B (zh) 2008-06-13 2018-01-21 曼凱公司 用於藥物傳輸之乾粉吸入器及系統
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN103751892B (zh) 2008-06-20 2017-03-01 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP3552603A1 (en) * 2009-03-18 2019-10-16 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
RU2445119C2 (ru) * 2010-05-25 2012-03-20 Сергей Викторович Чепур Фармацевтическая композиция и способ ее ингаляционного введения
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
GB2488992A (en) * 2011-03-10 2012-09-19 Advanced Ophthalmic Pharma Ltd Medicament dispenser
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
BR112013027391A2 (pt) * 2011-05-03 2017-01-17 Chiesi Farmaceutic S P A formulação farmacêutica, frasco e kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
JP6197515B2 (ja) * 2012-10-19 2017-09-20 大正製薬株式会社 医薬組成物
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
MX2015012931A (es) * 2013-03-13 2016-07-20 Forest Lab Holdings Ltd Composiciones farmaceuticas micronizadas.
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
WO2016004409A1 (en) * 2014-07-03 2016-01-07 Luxena Pharmaceuticals, Inc. Novel aerosol formulations of ondansetron and uses thereof
CN104274426A (zh) 2013-07-03 2015-01-14 陆克塞纳医药公司 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
RU2539374C1 (ru) * 2013-11-29 2015-01-20 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Высокодисперсная комбинированная фармацевтическая композиция беклометазона и сальбутамола с бета-глицином и способ ее получения
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
CN112656780A (zh) 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 用于吸入的干粉制剂
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2015187356A1 (en) * 2014-06-04 2015-12-10 Quick Joshua Ryan System and method for delivering an inhalable sugar formulation
RS58897B1 (sr) 2014-09-15 2019-08-30 Verona Pharma Plc Tečna inhalaciona formulacija koja sadrži rpl554
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MY191712A (en) * 2014-10-08 2022-07-09 Zambon Spa Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
CA2963445C (en) * 2014-10-08 2023-07-18 Zambon S.P.A. Pharmaceutical composition containing budesonide and formoterol
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
JP6908523B2 (ja) * 2015-08-05 2021-07-28 第一三共株式会社 ネブライザー用組成物
CN108348459A (zh) * 2015-09-09 2018-07-31 诺华股份有限公司 靶向递送喷雾干燥制剂到肺
US11844782B2 (en) * 2015-10-20 2023-12-19 Spepharm Ag Aqueous composition comprising dantrolene
IL260335B2 (en) 2016-02-01 2023-10-01 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation
BR112018076215A2 (pt) * 2016-06-30 2019-03-26 Philip Morris Products S.A. partículas e composições de nicotina
EP3478265A1 (en) * 2016-06-30 2019-05-08 Philip Morris Products S.a.s. Nicotine particles
WO2018071757A1 (en) 2016-10-14 2018-04-19 Pulmatrix Operating Company, Inc. Antifungal dry powders
WO2018163085A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US11344562B2 (en) 2017-08-15 2022-05-31 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
JP7493449B2 (ja) 2017-09-22 2024-05-31 ヴェクチュラ インコーポレイテッド ステアリン酸マグネシウムを含む乾燥粉末組成物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019136308A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
WO2020150460A1 (en) * 2019-01-18 2020-07-23 Milne Iii Donald A Micronized aspirin formulation
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
RU2730488C1 (ru) * 2019-08-20 2020-08-24 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Фармацевтическая композиция на основе глюкокортикостероида будесонида и фосфатидилхолина для сухой ингаляции
GB201914532D0 (en) * 2019-10-08 2019-11-20 Univ Of Huddersfield Lactose particles and method of production thereof
RU2735502C1 (ru) * 2020-01-09 2020-11-03 Федеральное государственное бюджетное учреждение науки Удмуртский федеральный исследовательский центр Уральского отделения Российской академии наук Аэрозоль для ингаляций при обструктивном бронхите
CN111202723A (zh) * 2020-02-15 2020-05-29 江苏艾立康药业股份有限公司 一种达芦那韦吸入干粉药物组合物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3009598B2 (ja) * 1994-02-18 2000-02-14 武田薬品工業株式会社 プレフィルドシリンジ
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
EA002562B1 (ru) 1997-09-29 2002-06-27 Инхэл Терапьютик Системз, Инк. Перфорированные микрочастицы и способ их использования
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
DE69907456T2 (de) * 1998-06-24 2004-03-25 Advanced Inhalation Research, Inc., Cambridge Grosse poröse partikel ausgestossen von einem inhalator
JP2003507410A (ja) * 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ,インコーポレイテッド 乾燥粉末製剤からの放出調節
AU775565B2 (en) 1999-10-29 2004-08-05 Novartis Ag Dry powder compositions having improved dispersivity
GB9929486D0 (en) 1999-12-15 2000-02-09 Glaxo Group Ltd Inhalation delivery apparatus and method
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1296651E (pt) 2000-06-27 2008-02-12 Vectura Ltd Método para fazer partículas para serem usadas numa composição farmacêutica
DE60131399T3 (de) * 2000-06-27 2019-11-14 Vectura Ltd. Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
US20020103139A1 (en) * 2000-12-01 2002-08-01 M. Weisspapir Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control
EP1487411B1 (en) 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Inhalable sustained therapeutic formulations
US20110123574A1 (en) * 2002-03-20 2011-05-26 Alkermes, Inc. Inhalable sustained therapeutic formulations
DK1531794T3 (en) 2002-06-28 2017-08-28 Civitas Therapeutics Inc INHALABLE EPINEPHRIN
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
PT1589947T (pt) * 2002-12-31 2016-09-05 Novartis Ag Formulação farmacêutica com um agente ativo insolúvel para administração pulmonar
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005025550A1 (en) 2003-09-15 2005-03-24 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EP1663164A2 (en) 2003-09-15 2006-06-07 Vectura Limited Methods for preparing pharmaceutical compositions
ITMI20040795A1 (it) 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa

Similar Documents

Publication Publication Date Title
JP2009512663A5 (ja)
CY1116503T1 (el) Φαρμακευτικες συνθεσεις για εισπνοη υπο μορφη ξηρης σκονης, διαλυματων ή εναιωρηματων
JP2009503104A5 (ja)
JP2016514686A5 (ja)
JP2008505857A5 (ja)
WO2005104712A3 (en) Dpi formulation containing sulfoalkyl ether cyclodextrin
JP2018162276A5 (ja)
JP2016513724A5 (ja)
WO2009092129A8 (en) Delayed release pharmaceutical composition of duloxetine
WO2006008517A3 (en) Use of dry powder compositions for pulmonary delivery
WO2009112273A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2016512248A5 (ja)
JP2009518276A5 (ja)
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2012503668A5 (ja)
JP2011525477A5 (ja)
JP2012502037A5 (ja)
JP2009537554A5 (ja)
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
NZ595904A (en) A novel formulation of meloxicam
JP2011157405A5 (ja)
JP2008515980A5 (ja)
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2008001645A (es) Composiciones de fexofendina en suspension farmaceutica oral.
JP2015522652A5 (ja)